Details of the Drug

General Information of Drug (ID: DMMZSXQ)

Drug Name
Azathioprine
Synonyms
Azamun; Azanin; Azasan; Azathioprin; Azathioprinum; Azathiopurine; Azatioprin; Azatioprina; Azothioprine; Ccucol; Cytostatics; Immuran; Imuran; Imurek; Imurel; Methylnitroimidazolylmercaptopurine; Muran; Azamun [Czech]; Azathioprine sodium; Azatiopr in; A 4638; BW 57322; Azamun (TN); Azasan (TN); Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; BW 57-322; Imuran (TN); Imurel (TN); [Methyl(nitroimidazolyl)mercaptopurine]; AI-981/34845012; BW-57-322; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; B. W. 57-322; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
Indication
Disease Entry ICD 11 Status REF
Lupus nephritis 4A40.0Y Approved [1]
Organ transplant rejection NE84 Approved [2]
Therapeutic Class
Immunosuppressive Agents
Affected Organisms
Humans and other mammals
ATC Code
L04AX01: Azathioprine
L04AX: Other immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04AX01: Azathioprine
L04AX: Other immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 277.27
Logarithm of the Partition Coefficient (xlogp) 0.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-2 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
60% of drug becomes completely available to its intended biological destination(s) [5]
Elimination
1% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [3]
Metabolism
The drug is metabolized via thiopurine methyltransferase, 6-thiouric acid by xanthine oxidase, or 6-thiosine-5'-monophosphate by hypoxanthine phosphoribosyltransferase [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 18.03324 micromolar/kg/day [7]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Bone marrow toxicity Not Available NT5C1A OTS7UF36 [8]
Chemical Identifiers
Formula
C9H7N7O2S
IUPAC Name
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
Canonical SMILES
CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
InChI
InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)
InChIKey
LMEKQMALGUDUQG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2265
ChEBI ID
CHEMBL1542
CAS Number
446-86-6
UNII
MRK240IY2L
DrugBank ID
DB00993
TTD ID
D07QCE
VARIDT ID
DR00113
INTEDE ID
DR0164
ACDINA ID
D00054
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Amidophosphoribosyltransferase (PPAT) TTZFTY4 PUR1_HUMAN Inhibitor [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [11]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Substrate [12]
Thiopurine methyltransferase (TPMT) DEFQ8VO TPMT_HUMAN Substrate [13]
Glutathione S-transferase alpha-2 (GSTA2) DEH49YS GSTA2_HUMAN Substrate [12]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Gene/Protein Processing [14]
1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 (PNPLA3) OTR4990X PLPL3_HUMAN Gene/Protein Processing [14]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [14]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Gene/Protein Processing [15]
2'-5'-oligoadenylate synthase 3 (OAS3) OT6E5FYS OAS3_HUMAN Gene/Protein Processing [15]
2-iminobutanoate/2-iminopropanoate deaminase (RIDA) OTW4098I RIDA_HUMAN Gene/Protein Processing [14]
2-phosphoxylose phosphatase 1 (PXYLP1) OTX8T7F6 PXYP1_HUMAN Gene/Protein Processing [14]
Abnormal spindle-like microcephaly-associated protein (ASPM) OTKXQMNA ASPM_HUMAN Gene/Protein Processing [14]
Acetyl-CoA acetyltransferase, cytosolic (ACAT2) OTZ092ZJ THIC_HUMAN Gene/Protein Processing [14]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Gene/Protein Processing [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Azathioprine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Belatacept DMXLYQF Moderate Additive immunosuppressive effects by the combination of Azathioprine and Belatacept. Transplant rejection [NE84] [16]
Coadministration of a Drug Treating the Disease Different from Azathioprine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Idarubicin DMM0XGL Moderate Additive myelosuppressive effects by the combination of Azathioprine and Idarubicin. Acute myeloid leukaemia [2A60] [16]
Siltuximab DMGEATB Moderate Additive immunosuppressive effects by the combination of Azathioprine and Siltuximab. Anemia [3A00-3A9Z] [16]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Roflumilast. Asthma [CA23] [17]
Dupilumab DMOAD2Y Moderate Additive immunosuppressive effects by the combination of Azathioprine and Dupilumab. Atopic eczema [EA80] [16]
Lomustine DMMWSUL Moderate Additive myelosuppressive effects by the combination of Azathioprine and Lomustine. Brain cancer [2A00] [16]
Eribulin DM1DX4Q Moderate Additive myelosuppressive effects by the combination of Azathioprine and Eribulin. Breast cancer [2C60-2C6Y] [16]
Talazoparib DM1KS78 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Talazoparib. Breast cancer [2C60-2C6Y] [16]
Ixabepilone DM2OZ3G Moderate Additive immunosuppressive effects by the combination of Azathioprine and Ixabepilone. Breast cancer [2C60-2C6Y] [16]
LY2835219 DM93VBZ Moderate Additive myelosuppressive effects by the combination of Azathioprine and LY2835219. Breast cancer [2C60-2C6Y] [16]
Pralatrexate DMAO80I Moderate Additive myelosuppressive effects by the combination of Azathioprine and Pralatrexate. Breast cancer [2C60-2C6Y] [16]
Palbociclib DMD7L94 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Palbociclib. Breast cancer [2C60-2C6Y] [16]
Thiotepa DMIZKOP Moderate Additive immunosuppressive effects by the combination of Azathioprine and Thiotepa. Breast cancer [2C60-2C6Y] [16]
Cabazitaxel DMPAZHC Moderate Additive immunosuppressive effects by the combination of Azathioprine and Cabazitaxel. Breast cancer [2C60-2C6Y] [16]
Bosutinib DMTI8YE Moderate Additive myelosuppressive effects by the combination of Azathioprine and Bosutinib. Breast cancer [2C60-2C6Y] [16]
Anisindione DM2C48U Moderate Antagonize the effect of Azathioprine when combined with Anisindione. Coagulation defect [3B10] [18]
Aflibercept DMT3D5I Moderate Additive immunosuppressive effects by the combination of Azathioprine and Aflibercept. Colorectal cancer [2B91] [16]
Capecitabine DMTS85L Moderate Additive immunosuppressive effects by the combination of Azathioprine and Capecitabine. Colorectal cancer [2B91] [16]
Mycophenolic acid DMRBMAU Moderate Additive immunosuppressive effects by the combination of Azathioprine and Mycophenolic acid. Crohn disease [DD70] [19]
Polatuzumab vedotin DMF6Y0L Moderate Additive immunosuppressive effects by the combination of Azathioprine and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [16]
Axicabtagene ciloleucel DMYHN59 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [16]
Flucytosine DM13VTW Moderate Additive myelosuppressive effects by the combination of Azathioprine and Flucytosine. Endocarditis [BB40-BA42] [16]
Bay 80-6946 DMLOS5R Moderate Additive myelosuppressive effects by the combination of Azathioprine and Bay 80-6946. Follicular lymphoma [2A80] [16]
Avapritinib DMK2GZX Moderate Additive immunosuppressive effects by the combination of Azathioprine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [16]
Colchicine DM2POTE Moderate Additive myelosuppressive effects by the combination of Azathioprine and Colchicine. Gout [FA25] [16]
177Lu-DOTATATE DMT8GVU Moderate Additive myelosuppressive effects by the combination of Azathioprine and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [16]
Procarbazine DMIK367 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Procarbazine. Hodgkin lymphoma [2B30] [16]
Brentuximab vedotin DMWLC57 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [16]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Azathioprine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [20]
Febuxostat DMDEXQ0 Major Decreased metabolism of Azathioprine caused by Febuxostat mediated inhibition of non-CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [21]
Balsalazide DM7I1T9 Moderate Decreased metabolism of Azathioprine caused by Balsalazide mediated inhibition of non-CYP450 enzyme. Indeterminate colitis [DD72] [22]
Olaratumab DMNYOIX Moderate Additive immunosuppressive effects by the combination of Azathioprine and Olaratumab. Kaposi sarcoma [2B57] [16]
Nelarabine DMB6VEG Moderate Additive immunosuppressive effects by the combination of Azathioprine and Nelarabine. Leukaemia [2A60-2B33] [16]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Azathioprine and Denosumab. Low bone mass disorder [FB83] [23]
Brigatinib DM7W94S Moderate Additive immunosuppressive effects by the combination of Azathioprine and Brigatinib. Lung cancer [2C25] [16]
Lurbinectedin DMEFRTZ Moderate Additive immunosuppressive effects by the combination of Azathioprine and Lurbinectedin. Lung cancer [2C25] [16]
Osimertinib DMRJLAT Moderate Additive immunosuppressive effects by the combination of Azathioprine and Osimertinib. Lung cancer [2C25] [16]
Belimumab DM3OBQF Moderate Additive immunosuppressive effects by the combination of Azathioprine and Belimumab. Lupus erythematosus [4A40] [16]
Primaquine DMWQ16I Moderate Additive myelosuppressive effects by the combination of Azathioprine and Primaquine. Malaria [1F40-1F45] [16]
Inotuzumab ozogamicin DMAC130 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [16]
Fludarabine DMVRLT7 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Fludarabine. Malignant haematopoietic neoplasm [2B33] [16]
Ofatumumab DM295PR Moderate Additive myelosuppressive effects by the combination of Azathioprine and Ofatumumab. Mature B-cell leukaemia [2A82] [16]
Obinutuzumab DM3BVAE Moderate Additive myelosuppressive effects by the combination of Azathioprine and Obinutuzumab. Mature B-cell leukaemia [2A82] [16]
Idelalisib DM602WT Moderate Additive myelosuppressive effects by the combination of Azathioprine and Idelalisib. Mature B-cell leukaemia [2A82] [16]
GDC-0199 DMH0QKA Moderate Additive immunosuppressive effects by the combination of Azathioprine and GDC-0199. Mature B-cell leukaemia [2A82] [16]
IPI-145 DMWA24P Moderate Additive immunosuppressive effects by the combination of Azathioprine and IPI-145. Mature B-cell leukaemia [2A82] [16]
Blinatumomab DMGECIJ Moderate Additive immunosuppressive effects by the combination of Azathioprine and Blinatumomab. Mature B-cell lymphoma [2A85] [16]
Ibrutinib DMHZCPO Moderate Additive immunosuppressive effects by the combination of Azathioprine and Ibrutinib. Mature B-cell lymphoma [2A85] [16]
Tisagenlecleucel DMM9BJD Moderate Additive immunosuppressive effects by the combination of Azathioprine and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [16]
Mercaptopurine DMTM2IK Major Additive immunosuppressive effects by the combination of Azathioprine and Mercaptopurine. Mature B-cell lymphoma [2A85] [24]
Ponatinib DMYGJQO Moderate Additive immunosuppressive effects by the combination of Azathioprine and Ponatinib. Mature B-cell lymphoma [2A85] [16]
Carfilzomib DM48K0X Moderate Additive myelosuppressive effects by the combination of Azathioprine and Carfilzomib. Multiple myeloma [2A83] [16]
Panobinostat DM58WKG Moderate Additive immunosuppressive effects by the combination of Azathioprine and Panobinostat. Multiple myeloma [2A83] [16]
Thalidomide DM70BU5 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Thalidomide. Multiple myeloma [2A83] [16]
Selinexor DMBD4K3 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Selinexor. Multiple myeloma [2A83] [16]
Belantamab mafodotin DMBT3AI Moderate Additive immunosuppressive effects by the combination of Azathioprine and Belantamab mafodotin. Multiple myeloma [2A83] [16]
Elotuzumab DMEYHG9 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Elotuzumab. Multiple myeloma [2A83] [16]
Daratumumab DMKCIUZ Moderate Additive myelosuppressive effects by the combination of Azathioprine and Daratumumab. Multiple myeloma [2A83] [16]
Melphalan DMOLNHF Moderate Additive immunosuppressive effects by the combination of Azathioprine and Melphalan. Multiple myeloma [2A83] [16]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Azathioprine and Tecfidera. Multiple sclerosis [8A40] [16]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Azathioprine and Siponimod. Multiple sclerosis [8A40] [16]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Azathioprine and Fingolimod. Multiple sclerosis [8A40] [25]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Azathioprine and Ocrelizumab. Multiple sclerosis [8A40] [16]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Azathioprine and Ozanimod. Multiple sclerosis [8A40] [17]
Romidepsin DMT5GNL Moderate Additive immunosuppressive effects by the combination of Azathioprine and Romidepsin. Mycosis fungoides [2B01] [16]
Decitabine DMQL8XJ Moderate Additive immunosuppressive effects by the combination of Azathioprine and Decitabine. Myelodysplastic syndrome [2A37] [16]
Nilotinib DM7HXWT Moderate Additive immunosuppressive effects by the combination of Azathioprine and Nilotinib. Myeloproliferative neoplasm [2A20] [16]
Ruxolitinib DM7Q98D Moderate Additive immunosuppressive effects by the combination of Azathioprine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [16]
Dasatinib DMJV2EK Moderate Additive immunosuppressive effects by the combination of Azathioprine and Dasatinib. Myeloproliferative neoplasm [2A20] [16]
Hydroxyurea DMOQVU9 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Hydroxyurea. Myeloproliferative neoplasm [2A20] [16]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Azathioprine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [16]
Busulfan DMXYJ9C Moderate Additive immunosuppressive effects by the combination of Azathioprine and Busulfan. Myeloproliferative neoplasm [2A20] [16]
Inebilizumab DMI0RHA Moderate Additive immunosuppressive effects by the combination of Azathioprine and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [16]
Atezolizumab DMMF8U0 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Atezolizumab. Non-small cell lung cancer [2C25] [16]
Olaparib DM8QB1D Moderate Additive immunosuppressive effects by the combination of Azathioprine and Olaparib. Ovarian cancer [2C73] [16]
Rucaparib DM9PVX8 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Rucaparib. Ovarian cancer [2C73] [16]
MK-4827 DMLYGH4 Moderate Additive myelosuppressive effects by the combination of Azathioprine and MK-4827. Ovarian cancer [2C73] [16]
Topotecan DMP6G8T Moderate Additive myelosuppressive effects by the combination of Azathioprine and Topotecan. Ovarian cancer [2C73] [16]
Tildrakizumab DMLW9HG Moderate Additive immunosuppressive effects by the combination of Azathioprine and Tildrakizumab. Psoriasis [EA90] [16]
Risankizumab DMM32GT Moderate Additive immunosuppressive effects by the combination of Azathioprine and Risankizumab. Psoriasis [EA90] [16]
Ixekizumab DMXW92T Moderate Additive immunosuppressive effects by the combination of Azathioprine and Ixekizumab. Psoriasis [EA90] [16]
Everolimus DM8X2EH Moderate Additive myelosuppressive effects by the combination of Azathioprine and Everolimus. Renal cell carcinoma [2C90] [16]
Temsirolimus DMS104F Moderate Additive myelosuppressive effects by the combination of Azathioprine and Temsirolimus. Renal cell carcinoma [2C90] [16]
Baricitinib DM4ONW5 Major Additive immunosuppressive effects by the combination of Azathioprine and Baricitinib. Rheumatoid arthritis [FA20] [16]
Tocilizumab DM7J6OR Moderate Additive immunosuppressive effects by the combination of Azathioprine and Tocilizumab. Rheumatoid arthritis [FA20] [16]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Canakinumab. Rheumatoid arthritis [FA20] [26]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Azathioprine and Rilonacept. Rheumatoid arthritis [FA20] [26]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Azathioprine and Golimumab. Rheumatoid arthritis [FA20] [27]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Azathioprine and Leflunomide. Rheumatoid arthritis [FA20] [17]
Abatacept DMSA8RU Moderate Additive immunosuppressive effects by the combination of Azathioprine and Abatacept. Rheumatoid arthritis [FA20] [16]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Azathioprine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [28]
Mogamulizumab DMISH0Z Moderate Additive immunosuppressive effects by the combination of Azathioprine and Mogamulizumab. Sezary syndrome [2B02] [16]
PDX-101 DM6OC53 Moderate Additive immunosuppressive effects by the combination of Azathioprine and PDX-101. Solid tumour/cancer [2A00-2F9Z] [16]
Ifosfamide DMCT3I8 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [16]
Docetaxel DMDI269 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [16]
Trabectedin DMG3Y89 Moderate Additive myelosuppressive effects by the combination of Azathioprine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [16]
Mitoxantrone DMM39BF Moderate Additive myelosuppressive effects by the combination of Azathioprine and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [16]
LEE011 DMMX75K Moderate Additive myelosuppressive effects by the combination of Azathioprine and LEE011. Solid tumour/cancer [2A00-2F9Z] [16]
Taxol DMUOT9V Moderate Additive myelosuppressive effects by the combination of Azathioprine and Taxol. Solid tumour/cancer [2A00-2F9Z] [16]
Doxorubicin DMVP5YE Moderate Additive myelosuppressive effects by the combination of Azathioprine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [16]
Pomalidomide DMTGBAX Moderate Additive myelosuppressive effects by the combination of Azathioprine and Pomalidomide. Systemic sclerosis [4A42] [16]
Plicamycin DM7C8YV Moderate Additive myelosuppressive effects by the combination of Azathioprine and Plicamycin. Testicular cancer [2C80] [16]
Deferiprone DMS2M7O Major Additive myelosuppressive effects by the combination of Azathioprine and Deferiprone. Thalassaemia [3A50] [16]
Trimetrexate DMDEA85 Moderate Additive immunosuppressive effects by the combination of Azathioprine and Trimetrexate. Toxoplasmosis [1F57] [16]
Olsalazine DMZW9HA Moderate Decreased metabolism of Azathioprine caused by Olsalazine mediated inhibition of non-CYP450 enzyme. Ulcerative colitis [DD71] [22]
Durvalumab DM4PVDY Moderate Additive immunosuppressive effects by the combination of Azathioprine and Durvalumab. Ureteral cancer [2C92] [16]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Azathioprine and Ganciclovir. Virus infection [1A24-1D9Z] [16]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Azathioprine and Valganciclovir. Virus infection [1A24-1D9Z] [16]
⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Azathioprine 100 mg tablet 100 mg Oral Tablet Oral
Azathioprine 50 mg tablet 50 mg Oral Tablet Oral
Azathioprine 75 mg tablet 75 mg Oral Tablet Oral
Azathioprine 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Azathioprine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7120).
3 FDA Approved Drug Products: Imuran Azathioprine Oral Tablets
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Prasanta Raghab Mohapatra, Deepak Aggarwal: Carbocisteine for acute exacerbations of COPD . 2008 Nov 8;372(9650):1630-1631.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77.
10 Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
11 Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000 Jun;21(6):1157-62.
12 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
13 Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402.
14 A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
15 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Havrda DE, Rathbun S, Scheid D "A case report of warfarin resistance due to azathioprine and review of the literature." Pharmacotherpy 21 (2001): 355-7. [PMID: 11253860]
19 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
20 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
21 Product Information. Uloric (febuxostat). Takeda Pharmaceuticals America, Lincolnshire, IL.
22 Lewis LD, Benin A, Szumlanski CL, et al. "Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction." Clin Pharmacol Ther 62 (1997): 464-75. [PMID: 9357398]
23 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
24 Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro. 2008;22(3):632-642. [PMID: 18222062]
25 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
26 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
27 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
28 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]